{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:15:08Z","timestamp":1789168508342,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Castrate\u2010resistant prostate cancer (CRPC) is a common malignancy with poor prognostic outcomes. Breast cancer\n                      <jats:italic>(BRCA<\/jats:italic>\n                      ) genes 1 and 2 mutations occur in prostate cancers and confer poorer prognoses. Somatic\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing can lead to inconclusive results, which can gatekeep patients from accessing targeted medications. We assessed the somatic\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing results among our cohort of CRPC patients for factors contributing to quality control (QC) failures and inconclusive testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a retrospective review of the records of all patients with CRPC attending our cancer care centers from 2020 to 2023. We identified the presence\/absence of somatic\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing results on their record. For those with returned results, we collected key information including biopsy characteristics, time from biopsy to\n                      <jats:italic>BRCA<\/jats:italic>\n                      result, and outcome of\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 147 patients with CRPC attended our service between January 2020 and 2023. A total of 54 patients (40%) had somatic\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing performed on a tumor biopsy sample. A total of 35 somatic tests (65%) returned an actionable (positive or negative) result. The remaining 19 (35%) returned as inconclusive\/QC failures. QC failures were significantly associated with a greater time from initial biopsy to somatic testing result (60 vs. 27 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.033). The type of tissue biopsied, tumor percentage in biopsy sample, tissue sampling method, and sampling hospital did not contribute significantly to QC failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A longer tissue retention interval from biopsy to somatic\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing is associated with a greater risk of inconclusive test results. We recommend a repeat biopsy for\n                      <jats:italic>BRCA<\/jats:italic>\n                      testing in CRPC patients where archival tissue is older than 5 years.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70011","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T03:04:27Z","timestamp":1756868667000},"page":"640-645","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Affecting Quality Control (QC) Failure Rates in Somatic Breast Cancer (\n                    <i>BRCA<\/i>\n                    ) Gene Testing in Castrate Resistant Prostate Cancer: Experiences From an Australian Cancer Care Centre"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-045X","authenticated-orcid":false,"given":"Cian","family":"O'Leary","sequence":"first","affiliation":[{"name":"Mater Cancer Care Centre Mater Hospital Brisbane  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yoong","sequence":"additional","affiliation":[{"name":"Mater Cancer Care Centre Mater Hospital Brisbane  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admire","family":"Matsika","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology Mater Hospital Brisbane  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niara","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Mater Hospital Brisbane Mater Misericordiae Ltd  South Brisbane Queensland Australia"},{"name":"Mater Clinical Unit, School of Clinical Medicine The University of Queensland  South Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"\u201cCancer Data in Australia \u201dAustralian Institute of Health and Welfare published August 31 2023 https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer\u2010data\u2010in\u2010australia\/contents\/overview\u2010of\u2010cancer\u2010in\u2010australia\u20102023."},{"key":"e_1_2_9_3_1","unstructured":"\u201cProstate Cancer in Australia Statistics.\u201dCancer Australia published September 15 2022 https:\/\/www.canceraustralia.gov.au\/cancer\u2010types\/prostate\u2010cancer\/statistics."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_9_5_1","unstructured":"\u201cNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer \u201dNCCN published July 17 2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"e_1_2_9_6_1","unstructured":"\u201cProstate Cancer: Statistics \u201dASCO published March 1 2023."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30410"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab053"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092435"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4986365"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109661"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3940"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22981"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101246"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030547"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23375"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030859"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00567"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0503-6"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:37:49Z","timestamp":1789166269000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/ajco.70011"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70011","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"2024-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}